Aethlon Medical, Inc. (AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today announced that James A. Joyce, Chief Executive Officer, will present at the Biotech Showcase 2015 Conference on Wednesday, January 14, 2015. Details of Aethlon Medical's presentation are as follows:
Biotech Showcase 2015
Wednesday, January 14, 2015
4:00 p.m. Pacific Time / 7:00 p.m. Eastern Time
Parc 55 Wyndham Union Square, San Francisco, CA
A live audio webcast of the presentation will be available on the Company's website in the Investor Relations section on the Events and Presentations . The webcast replay will be available approximately two hours after the presentation ends and will be accessible for one month.
About Biotech Showcase 2015
The Biotech Showcase 2015 conference takes place January 12-14, 2015, at the Parc 55 Wyndham Hotel located in Union Square, San Francisco, California. Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies an opportunity to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry's largest annual healthcare investor conferences. Now in its seventh year, Biotech Showcase is expected to attract upwards of 1,500 attendees.
The Company continues to advance their business through the ongoing commercial ramp of CytoSorb®
in 28 countries worldwide and a planned pivotal cardiac surgery trial in the U.S. On Dec 30th, the
Company announced, it has submitted an Investigational Device Exemption (IDE) application to the U.S.
Food and Drug Administration (FDA) to conduct its proposed clinical trial using CytoSorb® intraoperatively
in patients undergoing complex cardiac surgery requiring the use of a heart-lung machine.
The goal of CytoSorb® treatment is to reduce inflammatory mediators and proteins such as cytokines
and plasma free hemoglobin generated during surgery that can lead to serious post-operative
Mr. Vincent Capponi, Chief Operating Officer of CytoSorbents stated, "The submission of this IDE
application represents a major milestone for the Company, initiating the clinical trial process needed to
seek approval of CytoSorb® in the United States. With approximately half a million cardiac surgery
procedures such as valve replacement and coronary artery bypass graft surgeries each year in the U.S.
alone, and another one million in the rest of the world annually, we believe this represents a significant
potential commercial opportunity for the Company."Vista Partners LLC - January 2015
CytoSorb®, and the other products in the Company’s pipeline, may have significant upside considering
the massive markets they seek to address. CTSO has received validation of their technologies potential
from many large organizations in the form of research grants and other agreements including: BioCon,
DARPA, U.S. Army, U.S. Air Force, NIH/NHLBI, scientific advisors & analysts. The Company enjoys a
unique, high margin product and pipeline with little to no current competition and is currently selling
their flagship product CytoSorb® in Europe and the Middle East.
CytoSorbents Corporation (“CTSO” or the “Company”), which has seen its share price more than triple
since we initiated coverage in January 2014, is based in Monmouth Junction, NJ, and is a publicly
traded, critical care immunotherapy focused company using blood purification to treat life-threatening
illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can
actively remove toxic substances from blood and other bodily fluids by pore capture and surface
adsorption. Each polymer bead contains millions of pores and channels that can be modified to remove
substances as small as drugs, to substances as large as antibodies. The Company is on the “ground floor”
of commercialization and positioned to potentially create significant value with their product, CytoSorb®,
which has the potential to revolutionize critical care medicine; save lives, and reduce healthcare costs.
CytoSorb is as an extracorporeal cytokine adsorber, and can be used with standard hemodialysis
machines in any situation where cytokines are elevated. This includes a diverse range of conditions
where cytokines are driving a potentially dangerous inflammatory response, including acute critical
illnesses such as sepsis and infection, burn injury, trauma, acute respiratory distress syndrome, severe
acute pancreatitis, liver failure, influenza, and complications of cardiac surgery, as well as in other more
chronic diseases such as cancer, cancer cachexia, autoimmune diseases, and others.
CytoSorbents began trading on the Nasdaq on Dec. 23, 2014. This up-listing to NASDAQ is a significant
corporate milestone for CytoSorbents, and is the latest in a series of important accomplishments for the
About OneMedForum 2015
OneMedForum 2015 is a leading annual healthcare-focused investor conference bringing together more than 100 presenting growth companies and over 1,300 investors. By connecting companies and investors, the forum helps advance the firms shaping the future of health and medicine. This year, OneMedForum plans to launch OneMedMarket, a marketplace for builders and financiers of healthcare growth companies. Public companies will also be featured on OneMedTV through live streaming of their company presentations as well as the distribution of interviews with CEOs.
The Society of Critical Care Medicine (SCCM) is a non-profit organization that represents nearly 16,000 highly trained professionals in more than 100 countries whose collective goal is to secure the highest quality care for all critically ill and injured patients. The SCCM envisions a day when all such patients are cared for by a dedicated team of physicians, nurses, and other medical professionals specifically trained in critical care. The organization publishes Critical Care Medicine, the premier peer-reviewed, scientific journal in critical care, as well as Pediatric Critical Care Medicine, the first scientific, peer-reviewed journal to focus exclusively on pediatric and neonatal critical care.
CytoSorbents Corporation (NASDAQ CM: CTSO), a critical care immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation in critically-ill and cardiac surgery patients, announced that Dr. Phillip Chan, Chief Executive Officer, will present at the OneMedForum 2015 conference on Monday, January 12, 2015 at 2:00PM PST in the Marriott Marquis Hotel in San Francisco, California. A copy of the presentation will be posted to the Company's website following the conference. The conference is run concurrently with, but independently from, the 33rd Annual JP Morgan Healthcare Conference in San Francisco (January 12-15, 2015), one of the largest and most influential international healthcare conferences. During the conference, Dr. Chan will be joined by Kathleen Bloch, Chief Financial Officer, and Chris Cramer, Vice President of Business Development to meet with many analysts and investors.
In addition, CytoSorbents will exhibit at the upcoming Society of Critical Care Medicine (SCCM) 44th Critical Care Congress from January 17-19, 2015 at the Phoenix Convention Center in Phoenix, Arizona. More than 4,000 critical care clinicians from the U.S. and abroad are expected to attend. The Company will be showcasing its CytoSorb® blood purification therapy and discussing with U.S.-based clinicians the various treatment successes to date in critical care medicine, such as in sepsis, influenza, burn injury, trauma, acute lung injury, pancreatitis, liver failure, treatment of post-operative inflammation, and others. CytoSorb® is approved in the European Union and being marketed in 28 countries around the world, but is not yet approved in the United States.
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, obtained positive results from preclinical tests in which AC5™ was subjected to a battery of high-throughput in vitro safety assessments for biological interactions in standardized testing panels of receptors on the surface of cells and protein kinase enzymes inside cells. These receptors and enzymes represent important biochemical "switches," and interactions with them could indicate biological activity with the potential for toxicity. AC5 is a unique development-stage hemostasis product being evaluated to control bleeding and fluid loss in order to provide faster and safer surgical and interventional care.
In this in vitro study panel, AC5 tested in relevant amounts had no interactions with the examined 71 individual cell receptors or 211 separate cell kinase enzymes. These outcomes support AC5 as a non-toxic product to biochemical targets. Results from these safety interaction studies indicate that AC5's mechanism of action, which is the formation of a local physical-mechanical barrier, does not rely on AC5's interaction with known human receptors or enzymes to inhibit bleeding and leaking.
Arch Therapeutics President and CEO Terrence Norchi, MD, stated, "These differentiating results provide additional safety experience with AC5. The data highlights that there is no evidence of unintended interactions with the nearly 300 tested targets in the body, and it underscores the straightforward mechanism of action. We believe that AC5 has the potential to be a standout in terms of safety, efficacy and user friendliness."
Sentiment: Strong Buy
Green PolkaDot Box Incorporated (GPDB) "GPDB" America's premier online membership club for wholesale priced organic and non-GMO natural foods announced today that sales in all categories were up in December 2014 over November 2014 by approximately 65%. Growth in the Company's Health Merchant program remains strong; and Appethyl(R) sales started coming in strong at December's month's end. Sales of general goods in December were up by approximately 31% due to an increase in membership and reaching full inventory.
Early January sales of Appethyl(R), the new all natural appetite control product through Amazon exceeded management's expectations. Early sales of Health Merchantships--in anticipation of the national launch to occur later this month--are suggesting that January sales could beat November and December sales, combined.
Already, in early January between the 1st and 5th combined sales have exceeded $65,000 or about 37% of December total sales. GPDB management is confident that both Appethyl(R) and the Health Merchant program have broad appeal and the marketplace is just beginning to respond.
"Based on early sales results, we anticipate that customer growth in this first month of the year will increase from the current level of approximately 4,200 to more than 6,000," says GPDB CEO, Rod Smith, "and that we will see corresponding increases in monthly sales in January. The foundation that Greenpolkadotbox laid in 2014 is starting to pay off.
Article from Zacks
Cytosorbents Corporation (CTSO - Analyst Report) is a Medical Products industry stock that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on CTSO’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Cytosorbents could be a solid choice for investors.
Current Quarter Estimates for CTSO
In the past 30 days, 1 estimate has gone higher for Cytosorbents while no estimate has gone lower in the same time period. The trend has been pretty favorable too, with loss estimates narrowing from a loss of 25 cents a share 30 days ago, to a loss of 18 cents today, a move of 28%.
Current Year Estimates for CTSO
Meanwhile, Cytosorbents’s current year figures are also looking quite promising, with 1 estimate moving higher in the past month, compared to no lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of 92 cents per share 30 days ago to a loss of 87 cents per share today, move of 5.4%.
The stock has also started to move higher lately, adding 107.6% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future.
The present Ebola outbreak is considered the most severe on record and killed no less than 7,905 lives until now. The most common symptoms displayed by Ebola Virus carriers are fever, strong headaches, muscle distress, diarrhea, stomachache and external bleeding, as indicated by U.S. Centers for Disease Control and Prevention (CDC).
Ebola is contagious if healthy people come in contact with bodily fluids of the infected including “urine, saliva, sweat, feces, vomit, breast milk, and semen”, as per the CDC. Also, contact with tainted syringes or fruit bats and primates can prompt the spread of the ailment.
The device is also being tested in India to examine if it can speed up the viral load reduction when combined with a hepatitis C treatment.
The U.S. Food and Drug Administration approved clinical testing for an Ebola treatment this week. This new treatment is produced by Aethlon Medical Inc., a San-Diego based company. The treatment, called Aethlon’s Hemopurifier blood filter has been approved for patients infected with Ebola that are inside the United States.
This is not a drug but a bio-filtration gadget created for a one- time-use treatment to expel infections found within the blood system like the lethal and easily contagious Ebola virus. The medical device particularly focuses on any antiviral medication resistance of the virus. This type of treatment aims to serve as a basic countermeasure to Ebola (and different infections) which can’t be tackled with current medication treatments.
The endorsement of this Ebola treatment will permit research to be conducted in 10 areas and 20 subjects nationwide. Every selected patient will get a Hemopurifier daily administration. The devices will be used from six to eight hours until the Ebola viral load goes under 1,000 duplicates every blood ml.
Of course, the objective of the study is to establish a standard practice and assess how to successfully and effectively utilize the item to treat Ebola worldwide.
According to Aethlon reports, the Hemopurifier treatment was successful when a patient in a Critical Ebola condition received the treatment in Frankfurt University Hospital in Germany. The virus duplicates per mL of blood with the given patient were of 400,000. After being administered a 6.5-hour treatment the Ebola virus duplicates drastically tumbled to 1,000 per mL of blood.
At the time Aethlon started its treatment, the patient was not conscious and was struggling with multiple organ failure, being on the verge of dying. After the treatment his condition improved significantly. Slowly the patient was completely recovered and was able to return home to his family.
Not going to argue with you Karen, just do some research on your own instead of getting all your news from CBS.
Aethlon Medical Inc said the U.S. Food and Drug Administration approved testing of the company's experimental device in Ebola patients.
Patients will be administered for six to eight hours daily with the company's device, Hemopurifier, until the Ebola viral load drops below 1000 copies/ml, Aethlon said on Friday.
Aethlon's Hemopurifier selectively filters viruses and toxins from blood.
The approved protocol allows for a study to be conducted in up to 20 subjects in the United States, the company said.